Discontinuation of levetiracetam because of behavioral side effects - A case-control study

被引:118
作者
White, JR
Walczak, TS
Leppik, IE
Rarick, J
Tran, T
Beniak, TE
Matchinsky, DJ
Gumnit, RJ
机构
[1] MINCEP Epilepsy Care, Minneapolis, MN 55416 USA
[2] Univ Minnesota, Coll Pharm, Dept Neurol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Coll Pharm, Epilepsy Res & Educ Program, Minneapolis, MN 55455 USA
[4] N Hennepin Community Coll, Minneapolis, MN USA
[5] Univ Minnesota, Coll Pharm, Dept Neurosurg, Minneapolis, MN 55455 USA
关键词
D O I
10.1212/01.WNL.0000091865.46063.67
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Levetiracetam (LEV) is a recently approved anticonvulsant with proven efficacy and safety in the treatment of partial seizures. LEV may cause behavioral abnormalities that can be severe and require discontinuation of this drug. Risk factors for discontinuing LEV have not been established. Objective: To determine incidence of behavioral abnormalities severe enough to require discontinuation of LEV and identify risk factors for such behavioral abnormalities. Methods: All patients treated with LEV at MINCEP between January 2000 and February 2002 constituted the study population (n=553). Patients who had discontinued LEV for behavioral reasons were selected as index cases. Case controls were patients starting LEV immediately after the index case. Potential risk factors for LEV discontinuation included age, gender, cognitive function, history of psychiatric diagnosis, epilepsy syndrome, number of antiepileptic drugs, titration rate, maximum dose of LEV, and LEV level at maximum dose. Results: Thirty-eight patients (6.9%) discontinued LEV because of behavioral abnormalities. Variables associated with LEV discontinuation included faster titration rate to maximal dose, history of a psychiatric disorder, and diagnosis of symptomatic generalized epilepsy. Patients who discontinued LEV owing to behavioral reasons had significantly lower maximum LEV doses than controls. Conclusions: This study identified variables associated with discontinuation of LEV due to behavioral abnormalities. Slower titration of LEV should be considered in those patients at higher risk of discontinuing LEV for behavioral reasons.
引用
收藏
页码:1218 / 1221
页数:5
相关论文
共 12 条
[1]  
Asconape Jorge J., 2001, Epilepsia, V42, P299
[2]   Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy [J].
Ben-Menachem, E ;
Falter, T .
EPILEPSIA, 2000, 41 (10) :1276-1283
[3]  
Bergey GK, 2001, NEUROLOGY, V56, pA335
[4]   Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].
Cereghino, JJ ;
Biton, V ;
Abou-Khalil, B ;
Dreifuss, F ;
Gauer, LJ ;
Leppik, I .
NEUROLOGY, 2000, 55 (02) :236-242
[5]   Safety profile of levetiracetam [J].
Harden, C .
EPILEPSIA, 2001, 42 :36-39
[6]   EDUCATION AND THE PREVALENCE OF DEMENTIA AND ALZHEIMERS-DISEASE [J].
KATZMAN, R .
NEUROLOGY, 1993, 43 (01) :13-20
[7]   The place of levetiracetam in the treatment of epilepsy [J].
Leppik, IE .
EPILEPSIA, 2001, 42 :44-45
[8]  
*MED EC CO INC, 2001, PHYS DESK REF, P3206
[9]  
Sadek AH, 2002, NEUROLOGY, V58, pA297
[10]   Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures [J].
Shorvon, SD ;
Löwenthal, A ;
Janz, D ;
Bielen, E ;
Loiseau, P .
EPILEPSIA, 2000, 41 (09) :1179-1186